Visumab 0.5mg Injection
Prescription Required
Product introduction
Visumab 0.5mg Injection is used for the treatment of eye diseases which are caused by diabetes, macular degeneration, and macular swelling. It reduces the abnormal growth and leakage of blood vessels in the eye that can cause vision loss.
Visumab 0.5mg Injection is used to treat some eye diseases that leads to blindness
Visumab 0.5mg Injection is used to treat some eye diseases that leads to blindness
Uses of Visumab Injection
- Diabetic eye disease
- Wet age-related macular degeneration
- Macular edema due to retinal vein occlusion
Benefits of Visumab Injection
In Diabetic eye disease
Diabetic eye disease is a group of eye problems seen in people with diabetes. It can lead to vision loss, weak eyesight or even blindness. Visumab 0.5mg Injection helps prevent this damage caused by diabetes and stops the worsening of vision. Consult your doctor if you have any doubts.
In Wet age-related macular degeneration
Macula is the part of the retina responsible for central vision. Wet age-related macular degeneration is an eye disorder that causes blurred vision or a blind spot in your visual field due to abnormal blood vessels that leak fluid or blood into the macula. This leads to vision problems. Visumab 0.5mg Injection helps prevent leakage of such abnormal blood vessels and therefore prevents vision loss. It is given as an injection by a doctor or nurse and should not be self-administered.
In Macular edema due to retinal vein occlusion
Retinal vein occlusion is a blockage of the small veins that carry blood away from the retina, which is that part of the eye that is responsible for vision. So, retinal vein occlusion often causes permanent damage to the retina and loss of vision. It can also lead to other eye problems. Sometimes there is a complete loss of vision almost immediately. Visumab 0.5mg Injection helps treat swelling of the macula that can cause vision disturbances.
Side effects of Visumab Injection
Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them
Common side effects of Visumab
- Conjunctival hemorrhage
- Eye pain
- Increased intraocular pressure
- Foreign body sensation in eyes
- Blurred vision
- Nausea
- Dry eye
- Eye itching
- Cataract
- Vitreous floaters
- Vitreous detachment
- Intraocular inflammation
- Eye irritation
- Increased lacrimation
- Eyelid inflammation
- Ocular hyperemia
- Retinal disorder
- Maculopathy
- Eye discomfort
- Posterior capsule opacification
- Injection site hemorrhage
- Nasopharyngitis (inflammation of the throat and nasal passages)
- Anemia (low number of red blood cells)
- Joint pain
- Renal failure
- Peripheral neuropathy (tingling and numbness of feet and hand)
- Gastro-esophageal reflux disease
- Hypercholesterolemia (high cholesterol)
- Bronchitis (inflammation of the airways)
How to use Visumab Injection
Your doctor or nurse will give you this medicine. Kindly do not self administer.
Safety advice
Alcohol
CONSULT YOUR DOCTOR
It is not known whether it is safe to consume alcohol with Visumab 0.5mg Injection. Please consult your doctor.
Pregnancy
CONSULT YOUR DOCTOR
Visumab 0.5mg Injection may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Breast feeding
SAFE IF PRESCRIBED
Visumab 0.5mg Injection is probably safe to use during breastfeeding. Limited human data suggests that the drug does not represent any significant risk to the baby.
Driving
UNSAFE
Visumab 0.5mg Injection may cause blurring of your vision for a short time just after its use. Do not drive until your vision is clear.
Kidney
SAFE IF PRESCRIBED
Visumab 0.5mg Injection is probably safe to use in patients with kidney disease. Limited data available suggests that dose adjustment of Visumab 0.5mg Injection may not be needed in these patients. Please consult your doctor.
Liver
SAFE IF PRESCRIBED
Visumab 0.5mg Injection is probably safe to use in patients with liver disease. Limited data available suggests that dose adjustment of Visumab 0.5mg Injection may not be needed in these patients. Please consult your doctor.
All substitutes
For informational purposes only. Consult a doctor before taking any medicines.
Visumab 0.5mg Injection
₹15000.0/Injection
Lucentis Injection
Novartis India Ltd
₹70160/injection
368% costlier
Quick tips
- It may cause temporary visual disturbances. Don't drive or do anything that requires mental focus until you know how Visumab 0.5mg Injection affects you.
- Inform your doctor if you experience increased eye pain and redness, blurred or decreased vision, or increased sensitivity to light.
- Wear sunglasses if your eyes feel sensitive to light
- Use eye drops if they are prescribed to you by your doctor.
- Ask your doctor if you should avoid any particular activities.
- Try to rest your eyes as much as possible (for at least a few hours).
Fact Box
Chemical Class
Monoclonal antibody (mAb)
Habit Forming
No
Therapeutic Class
OPHTHAL
Action Class
Vascular endothelial growth factor (VEGF) inhibitor for AMD
Patient concerns
FAQs
Who should not take Visumab 0.5mg Injection?
Visumab 0.5mg Injection should not be taken by individuals who are allergic to the medication or have an active eye infection.
What is the duration of treatment for Visumab 0.5mg Injection?
Visumab 0.5mg Injection is recommended to be initially administered by intravitreal injection (into the eye) once a month (approximately 28 days) for up to 3 months.
What precautions should I take after taking Visumab 0.5mg Injection?
After taking Visumab 0.5mg Injection:<br>a. You should not wash your face and hair or shower for 48 hours<br>b. Avoid rubbing your eyes<br>c. Avoid swimming for a week. Consult your doctor in case of any doubts<br>d. Do not wear contact lenses immediately after injection. You may wear spectacles instead<br>e. Give complete rest to your eyes and do not strain by looking at television, mobile phones, or computer screens for 1-2 days.
Want to share the information?
Disclaimer:
Tata 1mg's sole intention is to ensure that its consumers get information that is expert-reviewed, accurate and trustworthy. However, the information contained herein should NOT be used as a substitute for the advice of a qualified physician. The information provided here is for informational purposes only. This may not cover everything about particular health conditions, lab tests, medicines, all possible side effects, drug interactions, warnings, alerts, etc. Please consult your doctor and discuss all your queries related to any disease or medicine. We intend to support, not replace, the doctor-patient relationship.References
- Henderer JD, Rapuano CJ. Ocular Pharmacology. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. New York, New York: McGraw-Hill Medical; 2011. p. 1794.
- Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. pp. 1196-97.
- Lake DF, Briggs AD, Akporiaye ET. Immunopharmacology. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. 11th ed. New Delhi, India: Tata McGraw Hill Education Private Limited; 2009. p. 977.
- Drugs.com. Ranibizumab. [Accessed 04 Apr. 2019] (online) Available from:
- Ranibizumab. South San Francisco, California: Genentech, Inc.; 2006. [Accessed 23 Jan. 2019] (online) Available from:
- Ranibizumab. Camberley, Surrey: Novartis Pharmaceuticals UK Ltd.; 2007 [revised 26 Jul. 2018]. [Accessed 04 Apr. 2019] (online) Available from:
Marketer details
Name: Reliance Life Sciences
Address: Dhirubhai Ambani Life Sciences Centre, R-282, TTC Area of MIDC, Thane-Belapur Road, Rabale, Navi Mumbai 400 701
Country of origin: India
Lab tests offered by us
Related/Popular tests
MRP
₹15000
Inclusive of all taxes
1.0 Injection in 1 vial
SOLD OUT